Loading…
Cellectar Biosciences, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in CLRB.
▼ -99.3% over 5Y.
today you would have $6.45▼ -99.4%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $2.95 | $9.00 | $83.10 | $51.30 | |
| P/B | 1.5x | 1.5x | 1.0x | — | 2.0x |
| EPS | -$8.35 | -$41.89 | -$105.00 | -$121.50 | |
| ROE | -311.87% | -255.25% | -311.87% | — | -389.94% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| NXTCNextCure, Inc. | $5.18 | — | 1.7x | — | -204.56% | $23.71M |
| AYTUAYTU Biopharma Inc | $2.25 | — | 0.7x | — | -97.42% | $24.15M |
| BFRIBiofrontera Inc. | $1.59 | — | 3.8x | — | -988.35% | $23.62M |
| ENLVEnlivex Ltd. | $1.35 |
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. It also develops CLR 121125, an iodine-125 Auger-emitting radioconjugate program; and CLR 225, an actinium-225 based radioconjugate program. The company has collaborative with Orano Med to develop alpha emitter lead-212 conjugated to phospholipid ether series; and LegoChem Bio. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.
Company description provided by Yahoo Finance.
| 0.0x |
| 0.0x |
| — |
| 126.17% |
| $23.61M |
| TVRDTvardi Therapeutics, Inc. | $1.82 | — | 1.2x | — | -126.19% | $24.28M |
| JSPRJasper Therapeutics, Inc. | $0.70 | — | 14.0x | — | -255.04% | $23.28M |